

25 Sep 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: a look at Alzheimer's drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk's cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 September 2022, including: a look at Alzheimer's drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; [Novo Nordisk A/S](#)'s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[The Moment Of Truth For Three Alzheimer's Drugs Beckons: What To Expect](#)" - Scrip, 16 Sep, 2022.)

(Also see "[US-China Decoupling Gets On Biotech's Nerves](#)" - Scrip, 20 Sep, 2022.)

(Also see "[Seven Potential Blockbuster Approvals To Look Out For In 2023](#)" - Scrip, 19 Sep, 2022.)

(Also see "[Novo Nordisk Committed To Advancing In Cardiovascular](#)" - Scrip, 20 Sep, 2022.)

(Also see "[*Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections*](#)" - Scrip, 20 Sep, 2022.)

[Click here to explore this interactive content online](#) ✨